Clinical trial NCT03423602: Safety and Performance Study of Large Hole Vascular Closure Device FIV
Official title: Clinical Investigation Plan (CIP) for Safety and Performance Study of Large Hole Vascular Closure Device - FRONTIER IV Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Percutaneous CFA Arteriotomy Closure
Keywords: Percutaneous vascular closure device
Large hole closure device
Arteriotomy closure
Vascular closure device
Lead sponsor: Vivasure Medical Limited
Sponsor class: INDUSTRY
First posted: 2018-02-06
Enrollment: 75
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: prospective, multi-centred, non-randomized study
Primary purpose: TREATMENT

Brief summary: The purpose of this Clinical Investigation Plan (CIP) is to:

1. Confirm the safety and performance of the PerQseal® large hole closure system.
2. To expand its indications of use to include common femoral arteriotomies created with 12 to 20 F sheaths in patients undergoing endovascular procedures.

Detailed description: This study will be a prospective, multi-centred, non-randomized study to investigate the safety and performance of the PerQseal® in 75 patients in approximately 10 European investigational sites.

The study shall not be blinded prior to, during or post the procedure. All patients undergoing an endovascular procedure requiring an arteriotomy created by 12 to 20 F sheaths, via the common femoral artery will be screened against the inclusion/exclusion criteria. If the patient meets the requirements of the clinical investigation, they shall be invited to participate, provide informed consent and shall subsequently be assigned a subject number.

All subjects shall have an immediately post procedure, \~24 hour, 1 and 3 month follow-up assessment. Safety data from the follow-ups will be assessed by the Data Safety Monitoring Committee on a continuous basis.

Eligibility criteria: Inclusion Criteria:

* Over 18 years of age.
* Subject is willing and able to provide appropriate study-specific informed consent, follow protocol procedures, and comply with follow-up visit requirements.
* Clinically indicated for an endovascular procedure using a common femoral arteriotomy created by a 12 - 20 F sheath.

Exclusion Criteria:

* Severe acute non-cardiac systemic disease or terminal illness with a life expectancy of less than six months.
* Evidence of systemic bacterial or cutaneous infection, including groin infection.
* Known bleeding diathesis, definite or potential coagulopathy, platelet count \< 100,000/μl or patients on long term anticoagulants with an INR greater than 1.2 at time of procedure or known type II heparin-induced thrombocytopenia.
* Severe; claudication or peripheral vascular disease (e.g. Rutherford category 3 or greater or ABI \< 0.5), documented untreated iliac artery diameter stenosis \> 50% or previous bypass surgery/stent placement in the common femoral artery of ipsilateral limb.
* Known allergy to any of the materials used in the PerQseal®.
* Subject has undergone a percutaneous procedure using a non-absorbable vascular closure device (excluding suture mediated) for haemostasis in the ipsilateral target leg.
* Patients that have undergone a percutaneous procedure in the ipsilateral leg, within the previous 30 days.
* Patients that have undergone a percutaneous procedure using an absorbable intravascular closure device for haemostasis, in the ipsilateral leg, within the previous 90 days.
* Evidence of arterial diameter stenosis \> 20% or anterior or circumferential calcification within 20 mm proximal or distal to target arteriotomy site based on pre-procedure CT angiography.
* Females who are pregnant or lactating or in fertile period not taking adequate contraceptives. A pregnancy test may be performed.
* Patients that have a lower extremity amputation from the ipsilateral or contralateral limb.
* Arterial access other than common femoral artery obtained for ipsilateral target leg.
* Subject has a tissue tract expected to be greater than 10 cm.
* Use of thrombolytic agents within 24 hours prior to or during the endovascular procedure which causes fibrinogen \< 100 mg/dl.
* Significant blood loss/transfusion (defined as requiring transfusion of 4 or more units of blood products) during index procedure or within 30 days prior to index procedure.
* Activated clotting time (ACT) \> 350 seconds immediately prior to sheath removal or if ACT measurements are expected to be \> 350 seconds for more than 24 hours after index procedure.
* Target puncture site is located in a vascular graft.
* Target arteriotomy in the profunda femoris or superficial femoral artery or is in common femoral artery, but within 10 mm proximal of the bifurcation of the Superficial Femoral /Profunda Femoris artery.
* PerQseal® Introducer-sheath to ipsilateral femoral artery diameter ratio is greater than or equal to 1.05.
* Subjects with an acute haematoma of any size, arteriovenous fistula or pseudoaneurysm at the target access site; or angiographic evidence of arterial laceration or dissection within the external iliac or femoral artery before the use of the PerQseal® closure device.

Primary outcomes:
measure: Major Vascular Complications [Safety]
timeFrame: up to 1 month post implantation
Secondary outcomes:
measure: Minor Vascular Complications [Safety]
timeFrame: up to 1 month from implantation
measure: Study Device Technical Success Rate [Performance]
timeFrame: within 24 hours
Other outcomes:
Locations:
city: Berlin-Mitte
country: Germany
facility: The Charité - Universitätsmedizin
state: Berlin
city: Bad Nauheim
country: Germany
facility: Kerckhoff Klinik, Bad Nauheim
state: Hesse
city: Frankfurt am Main
country: Germany
facility: CardioVasculäres Centrum
state: Hesse
city: Essen
country: Germany
facility: Contilia Heart and Vascular centre
state: North Rhine-Westphalia
city: Köln
country: Germany
facility: Uniklinik Köln, Herzzentrum
state: North Rhine-Westphalia
city: Muenster
country: Germany
facility: St Franziskus Hospital
state: North Rhine-Westphalia
city: Mainz
country: Germany
facility: Universitätsmedizin Mainz
state: Rhineland-Palatinate
city: Leipzig
country: Germany
facility: Medical Faculty of the University of Leipzig
state: Saxony
city: Hamburg
country: Germany
facility: Asklepios Klinik St. Georg Medizinische Abteilung
city: Blackrock
country: Ireland
facility: Blackrock Clinic
state: Dublin
city: Dublin
country: Ireland
facility: St James Hospital
Study officials:
affiliation: St Fraziskus Hospital, Muenster, Germany
name: Dr Arne Schwindt
role: PRINCIPAL_INVESTIGATOR
affiliation: Contilia Heart and Vascular centre, Essen, Germany
name: Dr Christoph Naber
role: PRINCIPAL_INVESTIGATOR
References: